A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)-amphetamine, p-methoxyamphetamine and harmaline.
D000470:Alkaloids / Q000494:pharmacology*; D000662:Amphetamines / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000201:enzymology; D003913:Dextroamphetamine / Q000494:pharmacology*; D006246:Harmaline / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D008928:Mitochondria / Q000201:enzymology; D008996:Monoamine Oxidase Inhibitors; D010624:Phenelzine / Q000494:pharmacology; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D014191:Tranylcypromine / Q000494:pharmacology
D000470:Alkaloids; D000662:Amphetamines; D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D014191:Tranylcypromine; D006246:Harmaline; D010624:Phenelzine; C100230:4-methoxyamphetamine; D003913:Dextroamphetamine